^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Prostate Cancer
    Drug:Vantas (histrelin acetate) (GnRH agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    12/16/2020
    Excerpt:
    VANTAS is a gonadotropin releasing hormone (GnRH) agonist indicated for the palliative treatment of advanced prostate cancer.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Prostate cancer: PRINCIPLES OF ANDROGEN DEPRIVATION THERAPY...ADT for Regional (N1,M0) Disease…Options for ADT are: LHRH agonist alone...Goserelin, histrelin, leuprolide, or triptorelin